- Home
- SLGL vs BANX Comparison
SLGL vs BANX Comparison
Compare SLGL & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLGL | BANX |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.7M | 172.0M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLGL | BANX |
|---|---|---|
| Price | $60.00 | $21.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $110.00 | N/A |
| AVG Volume (30 Days) | ★ 23.5K | 23.4K |
| Earning Date | 11-20-2025 | 06-17-2025 |
| Dividend Yield | N/A | ★ 9.66% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | $18,970,000.00 | ★ $29,467,794.00 |
| Revenue This Year | $122.71 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.88 |
| Revenue Growth | ★ 62.04 | 2.73 |
| 52 Week Low | $4.02 | $17.99 |
| 52 Week High | $75.00 | $21.67 |
Technical Indicators
Market Signals| Indicator | SLGL | BANX |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 42.38 |
| Support Level | $48.26 | $20.67 |
| Resistance Level | $65.17 | $21.79 |
| Average True Range (ATR) | 7.83 | 0.39 |
| MACD | -0.58 | -0.07 |
| Stochastic Oscillator | 63.05 | 34.78 |
Price Performance
Historical ComparisonAbout SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.